A Randomized, Double-Blind, Multicenter Phase III Clinical Trial Evaluating AL2846 Capsule Versus Placebo in Patients With Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma Who Failed Prior VEGFR-Targeted Therapy
Latest Information Update: 30 Apr 2025
At a glance
- Drugs AL 2846 (Primary)
- Indications Thyroid cancer
- Focus Registrational; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 25 Apr 2025 Status changed from not yet recruiting to recruiting.
- 13 Mar 2025 New trial record